Primary biliary cholangitisNews & Research
19 curated articles for Primary biliary cholangitis — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Current opinion in immunology May 21, 2026
Can we cure primary biliary cholangitis?
Primary biliary cholangitis (PBC) is a chronic immune-mediated liver disease characterized by progressive destruction of the intrahepatic bile ducts, leading to cholestasis, fibrosis, and eventual cirrhosis. Despite advances in understanding disease pathogenesis, treatment pathways are focused on ma...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Expert review of clinical immunology May 20, 2026
Primary biliary cholangitis: current insights and novel therapies.
Primary biliary cholangitis (PBC) may present asymptomatically or with potentially debilitating symptoms and can progress to cirrhosis despite first-line ursodeoxycholic acid (UDCA) therapy. A subset of patients exhibits inadequate response or intolerance, necessitating novel targeted approaches and...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Hepatology communications May 12, 2026
Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis.
Patients with primary biliary cholangitis (PBC) often suffer from debilitating symptoms, yet the overall symptom burden has not been systematically quantified. This study aims to systematically review the prevalence and severity of the symptom burden in PBC patients. We conducted a systematic search...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Hepatology international May 8, 2026
New therapies for primary biliary cholangitis.
Primary Biliary Cholangitis (PBC) is a cholestatic autoimmune liver disease of small bile ducts. Ursodeoxycholic acid (UDCA) was approved as a first line therapeutic option for PBC in 1997. It was later noted that 40% of patients with PBC are either non-responders or intolerant to UDCA. In 2016, obe...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Alimentary pharmacology & therapeutics Apr 17, 2026
Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.
Primary biliary cholangitis (PBC) is a chronic, immune-mediated liver disease characterised by cholestasis, progressive fibrosis and symptoms of pruritus and fatigue. Ursodeoxycholic acid (UDCA) is first-line therapy; however, many patients respond inadequately or are intolerant. Peroxisome prolifer...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Frontiers in immunology Apr 10, 2026
Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit.
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by cholestasis-driven bile duct injury and fibrosis. Biliary epithelial cells (BECs) play a central role in both bile homeostasis and immune regulation, and their metabolic and immune dysfunction is critical in PBC...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- The American journal of gastroenterology Apr 6, 2026
Impact of Alkaline Phosphatase Normalization on Complication-Free Survival in Primary Biliary Cholangitis.
Despite the widespread use of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC), many patients remain at risk of progression. Emerging data suggest that normalization of alkaline phosphatase (ALP) and total bilirubin (TB)-particularly when TB < 0.6 times the upper limit of normal (...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Gastroenterologia y hepatologia Apr 4, 2026
Spanish clinical practice guidelines for the diagnosis and management of cholestatic liver diseases in adult and pediatric population: Joint report from AEEH and SEGHNP.
Cholestatic liver diseases comprise a heterogeneous group of disorders affecting both adult and pediatric population, characterized by alterations in bile formation, secretion, or flow, leading to the accumulation of bile acids and other toxic substances in the liver. In recent years, advances in ne...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Nature reviews. Gastroenterology & hepatology Mar 30, 2026
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- International journal of molecular sciences Mar 28, 2026
Underestimated and Overlooked Factors in PBC Progression: Bacterial and Fungal Infections.
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by cholestasis, which can progress to end-stage liver disease and even hepatocellular carcinoma. Its onset is typically triggered by complex interactions between genetic and environmental factors. In recent years, ...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Mar 23, 2026
Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis.
The prevalence and clinical outcomes of recompensation in patients with decompensated cirrhosis remain unclear. We aimed to determine the prevalence and clinical outcomes among decompensated patients who achieve recompensation. We systematically searched PubMed and EMBASE from inception until July 1...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- The American journal of the medical sciences Mar 15, 2026
Relationship between depression and chronic liver disease: Potential role of antidepressants in modulating liver fibrosis.
Depression is a frequent comorbidity in chronic liver disease (CLD), including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), viral hepatitis, autoimmune hepatitis (AIH), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), hemochromatosis, and Wilson's disease...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Lipids in health and disease Mar 6, 2026
Lipidome remodeling in primary biliary cholangitis.
Primary biliary cholangitis (PBC) is a chronic, cholestatic liver disease characterized by progressive destruction of intrahepatic bile ducts, impaired bile flow, and complex disturbances in bile acid and lipid metabolism. PBC is associated with a distinctive dyslipidemic profile, marked by elevated...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Feb 22, 2026
Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-Analysis.
Primary biliary cholangitis (PBC) demonstrates significant geographical variability in its epidemiology. We aim to provide an updated estimate on the global and temporal trends of the prevalence and incidence of PBC from 1976 to 2024. We systematically searched three electronic databases from incept...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Alimentary pharmacology & therapeutics Feb 18, 2026
Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.
Nearly 40% of patients with primary biliary cholangitis (PBC) have an incomplete response to first-line ursodeoxycholic acid (UDCA) therapy. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, is an effective second-line treatment for PBC. Compared to the recently...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Advances in therapy Feb 16, 2026
Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States.
Lack of or delayed treatment of primary biliary cholangitis (PBC) is associated with worsening outcomes. This study assessed the real-world healthcare resource use (HRU) and costs of PBC in the USA to understand its economic burden by line of therapy. This retrospective study analyzed IQVIA PharMetr...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Current opinion in gastroenterology Feb 5, 2026
PBC-AIH variant syndrome: emerging new terminology and a new approach to diagnosis and management.
This review summarizes the recent developments of one of the most controversial entities in hepatology, variant syndromes of primary biliary cholangitis (PBC) with characteristics of autoimmune hepatitis (AIH). Recently a consensus process was initiated to find agreement on the terminology, diagnost...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Alimentary pharmacology & therapeutics Jan 29, 2026
Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis.
Biochemical non-response to ursodeoxycholic acid, as a first-line therapy, is associated with a heightened risk of clinical events in primary biliary cholangitis (PBC). Herein, we determine whether biochemical non-response to second-line therapy in obeticholic acid (OCA) is also predictive of long-t...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
- Journal of hepatology Jan 17, 2026
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.
Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis (PBC). However, the frequency and clinical relevance of discordant biochemical and LSM changes remain unclear. We aim to determine the performance of the most rec...
Why it matters: Recent peer-reviewed research on Primary biliary cholangitis that may be relevant for patients and caregivers.
More on Primary biliary cholangitis
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.